Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)

Polycystic ovary syndrome (PCOS) is the most common endorinopathy in fertile women with heterogeneous reproductive and metabolic phenotypes and unknown etiology. This study was undertaken to investigate the beneficial effect of selenium in management of letrozole induced PCOS and its role in modulat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of biochemistry and biophysics 2019-08, Vol.671, p.245-254
Hauptverfasser: Atef, Marwa Mohamed, Abd-Ellatif, Rania Nagi, Emam, Marwa Nagy, Abo El gheit, Rehab E., Amer, Alaa Ibrahim, Hafez, Yasser Mostafa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 254
container_issue
container_start_page 245
container_title Archives of biochemistry and biophysics
container_volume 671
creator Atef, Marwa Mohamed
Abd-Ellatif, Rania Nagi
Emam, Marwa Nagy
Abo El gheit, Rehab E.
Amer, Alaa Ibrahim
Hafez, Yasser Mostafa
description Polycystic ovary syndrome (PCOS) is the most common endorinopathy in fertile women with heterogeneous reproductive and metabolic phenotypes and unknown etiology. This study was undertaken to investigate the beneficial effect of selenium in management of letrozole induced PCOS and its role in modulating mitochondrial dynamics, and its associated signals. Twenty four adult female rats were enrolled and randomly divided into four equal groups; control group received 0.5% w/v carboxymethyl cellulose (CMC); PCOS group received letrozole (1 mg/kg, daily) in 0.5% CMC for 21 days. From day 22 to day 36, after letrozole PCOS induction, the (PCOS +Metformin) group received metformin (2 mg/kg, daily) while (PCOS + sodium selenite) group received sodium selenite (0.1 mg/kg, daily). All doses were given via oral gavage. At the study end, serum hormone levels, lipid profile and HOMA-IR were assessed. Ovaries were dissected, used for histopathological evaluation, immunohistochemical detection of B-cell lymphoma-2 (Bcl-2), and its associated X protein (Bax) expression, measurement of redox status, mitochondrial dynamics markers and citrate synthase (CS) activity. Furthermore Mitofusins 2 (Mfn2) and dynamin related protein 1 (Drp1) mRNA expression was assessed by real time PCR. Selenium treatment of PCOS rats succeeded, comparable to metformin, to greatly improve the PCOS associated endocrine and metabolic phenotypes and histopathological changes, mostly through modulating mitochondrial dynamics, anti-apoptotic action, alleviating oxidative stress and mitochondrial dysfunction. So, selenium could provide a novel therapeutic strategy for PCOS. •PCOS is a common endorinopathy but still with unsatisfactory management.•The search for treatment combating different lines of PCOS pathogenesis is needed.•Thus beneficial effect of selenium in modulating PCOS outcomes was investigated.•Selenium could provide a novel therapeutic strategy for PCOS.
doi_str_mv 10.1016/j.abb.2019.06.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2250631435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003986119302838</els_id><sourcerecordid>2250631435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-43b8460d02800bfe95564d41cb045544596cf4976ffdabde379208e210dca31e3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotuFH8AF-VgOCePYcRM4VSsoSJWKxHK2HHvS9SqJg-1UWn4IvxdHWzhyskZ6732eeYS8YVAyYPL9sdRdV1bA2hJkCdA-IxsGrSyAN-I52QAAL9pGsgtyGeMRgDEhq5fkgrOqZm3FN-T3_oBBz7gkZ-jsE07J6YH6nkZv3TLSiANOLiF1Ex0wBf_LD-tgF4M2O4aTOcXV7B91ONF4mmzwI9KgEx29xeED3evwgMlND3R0yZuDz5IVouc5eG0O9OoMybQM-ba7__7uFXnR6yHi66d3S358_rTffSnu7m-_7m7uCsNrngrBu0ZIsFA1AF2PbV1LYQUzHYi6FqJupelFey373urOIr9uK2iwYmCN5gz5llydc_NPfi4YkxpdNDgMekK_RFVVNUjORKZtCTtLTfAxBuzVHNyYd1YM1FqHOqpch1rrUCBVriN73j7FL92I9p_j7_2z4ONZgHnJR4dBReNwyqd1AU1S1rv_xP8BDY2deQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2250631435</pqid></control><display><type>article</type><title>Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Atef, Marwa Mohamed ; Abd-Ellatif, Rania Nagi ; Emam, Marwa Nagy ; Abo El gheit, Rehab E. ; Amer, Alaa Ibrahim ; Hafez, Yasser Mostafa</creator><creatorcontrib>Atef, Marwa Mohamed ; Abd-Ellatif, Rania Nagi ; Emam, Marwa Nagy ; Abo El gheit, Rehab E. ; Amer, Alaa Ibrahim ; Hafez, Yasser Mostafa</creatorcontrib><description>Polycystic ovary syndrome (PCOS) is the most common endorinopathy in fertile women with heterogeneous reproductive and metabolic phenotypes and unknown etiology. This study was undertaken to investigate the beneficial effect of selenium in management of letrozole induced PCOS and its role in modulating mitochondrial dynamics, and its associated signals. Twenty four adult female rats were enrolled and randomly divided into four equal groups; control group received 0.5% w/v carboxymethyl cellulose (CMC); PCOS group received letrozole (1 mg/kg, daily) in 0.5% CMC for 21 days. From day 22 to day 36, after letrozole PCOS induction, the (PCOS +Metformin) group received metformin (2 mg/kg, daily) while (PCOS + sodium selenite) group received sodium selenite (0.1 mg/kg, daily). All doses were given via oral gavage. At the study end, serum hormone levels, lipid profile and HOMA-IR were assessed. Ovaries were dissected, used for histopathological evaluation, immunohistochemical detection of B-cell lymphoma-2 (Bcl-2), and its associated X protein (Bax) expression, measurement of redox status, mitochondrial dynamics markers and citrate synthase (CS) activity. Furthermore Mitofusins 2 (Mfn2) and dynamin related protein 1 (Drp1) mRNA expression was assessed by real time PCR. Selenium treatment of PCOS rats succeeded, comparable to metformin, to greatly improve the PCOS associated endocrine and metabolic phenotypes and histopathological changes, mostly through modulating mitochondrial dynamics, anti-apoptotic action, alleviating oxidative stress and mitochondrial dysfunction. So, selenium could provide a novel therapeutic strategy for PCOS. •PCOS is a common endorinopathy but still with unsatisfactory management.•The search for treatment combating different lines of PCOS pathogenesis is needed.•Thus beneficial effect of selenium in modulating PCOS outcomes was investigated.•Selenium could provide a novel therapeutic strategy for PCOS.</description><identifier>ISSN: 0003-9861</identifier><identifier>EISSN: 1096-0384</identifier><identifier>DOI: 10.1016/j.abb.2019.06.009</identifier><identifier>PMID: 31251923</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Blood Glucose - metabolism ; Citrate (si)-Synthase - metabolism ; Estradiol - metabolism ; Female ; Insulin - metabolism ; Letrozole ; Lipid Metabolism - drug effects ; Metformin ; Mitochondria - metabolism ; Mitochondrial dynamics ; Ovary - pathology ; Oxidation-Reduction - drug effects ; Polycystic ovary syndrome ; Polycystic Ovary Syndrome - chemically induced ; Polycystic Ovary Syndrome - drug therapy ; Progesterone - metabolism ; Rats ; Selenium ; Sodium Selenite - therapeutic use ; Testosterone - metabolism</subject><ispartof>Archives of biochemistry and biophysics, 2019-08, Vol.671, p.245-254</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-43b8460d02800bfe95564d41cb045544596cf4976ffdabde379208e210dca31e3</citedby><cites>FETCH-LOGICAL-c353t-43b8460d02800bfe95564d41cb045544596cf4976ffdabde379208e210dca31e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0003986119302838$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31251923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atef, Marwa Mohamed</creatorcontrib><creatorcontrib>Abd-Ellatif, Rania Nagi</creatorcontrib><creatorcontrib>Emam, Marwa Nagy</creatorcontrib><creatorcontrib>Abo El gheit, Rehab E.</creatorcontrib><creatorcontrib>Amer, Alaa Ibrahim</creatorcontrib><creatorcontrib>Hafez, Yasser Mostafa</creatorcontrib><title>Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)</title><title>Archives of biochemistry and biophysics</title><addtitle>Arch Biochem Biophys</addtitle><description>Polycystic ovary syndrome (PCOS) is the most common endorinopathy in fertile women with heterogeneous reproductive and metabolic phenotypes and unknown etiology. This study was undertaken to investigate the beneficial effect of selenium in management of letrozole induced PCOS and its role in modulating mitochondrial dynamics, and its associated signals. Twenty four adult female rats were enrolled and randomly divided into four equal groups; control group received 0.5% w/v carboxymethyl cellulose (CMC); PCOS group received letrozole (1 mg/kg, daily) in 0.5% CMC for 21 days. From day 22 to day 36, after letrozole PCOS induction, the (PCOS +Metformin) group received metformin (2 mg/kg, daily) while (PCOS + sodium selenite) group received sodium selenite (0.1 mg/kg, daily). All doses were given via oral gavage. At the study end, serum hormone levels, lipid profile and HOMA-IR were assessed. Ovaries were dissected, used for histopathological evaluation, immunohistochemical detection of B-cell lymphoma-2 (Bcl-2), and its associated X protein (Bax) expression, measurement of redox status, mitochondrial dynamics markers and citrate synthase (CS) activity. Furthermore Mitofusins 2 (Mfn2) and dynamin related protein 1 (Drp1) mRNA expression was assessed by real time PCR. Selenium treatment of PCOS rats succeeded, comparable to metformin, to greatly improve the PCOS associated endocrine and metabolic phenotypes and histopathological changes, mostly through modulating mitochondrial dynamics, anti-apoptotic action, alleviating oxidative stress and mitochondrial dysfunction. So, selenium could provide a novel therapeutic strategy for PCOS. •PCOS is a common endorinopathy but still with unsatisfactory management.•The search for treatment combating different lines of PCOS pathogenesis is needed.•Thus beneficial effect of selenium in modulating PCOS outcomes was investigated.•Selenium could provide a novel therapeutic strategy for PCOS.</description><subject>Animals</subject><subject>Blood Glucose - metabolism</subject><subject>Citrate (si)-Synthase - metabolism</subject><subject>Estradiol - metabolism</subject><subject>Female</subject><subject>Insulin - metabolism</subject><subject>Letrozole</subject><subject>Lipid Metabolism - drug effects</subject><subject>Metformin</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondrial dynamics</subject><subject>Ovary - pathology</subject><subject>Oxidation-Reduction - drug effects</subject><subject>Polycystic ovary syndrome</subject><subject>Polycystic Ovary Syndrome - chemically induced</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Progesterone - metabolism</subject><subject>Rats</subject><subject>Selenium</subject><subject>Sodium Selenite - therapeutic use</subject><subject>Testosterone - metabolism</subject><issn>0003-9861</issn><issn>1096-0384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhS0EotuFH8AF-VgOCePYcRM4VSsoSJWKxHK2HHvS9SqJg-1UWn4IvxdHWzhyskZ6732eeYS8YVAyYPL9sdRdV1bA2hJkCdA-IxsGrSyAN-I52QAAL9pGsgtyGeMRgDEhq5fkgrOqZm3FN-T3_oBBz7gkZ-jsE07J6YH6nkZv3TLSiANOLiF1Ex0wBf_LD-tgF4M2O4aTOcXV7B91ONF4mmzwI9KgEx29xeED3evwgMlND3R0yZuDz5IVouc5eG0O9OoMybQM-ba7__7uFXnR6yHi66d3S358_rTffSnu7m-_7m7uCsNrngrBu0ZIsFA1AF2PbV1LYQUzHYi6FqJupelFey373urOIr9uK2iwYmCN5gz5llydc_NPfi4YkxpdNDgMekK_RFVVNUjORKZtCTtLTfAxBuzVHNyYd1YM1FqHOqpch1rrUCBVriN73j7FL92I9p_j7_2z4ONZgHnJR4dBReNwyqd1AU1S1rv_xP8BDY2deQ</recordid><startdate>20190815</startdate><enddate>20190815</enddate><creator>Atef, Marwa Mohamed</creator><creator>Abd-Ellatif, Rania Nagi</creator><creator>Emam, Marwa Nagy</creator><creator>Abo El gheit, Rehab E.</creator><creator>Amer, Alaa Ibrahim</creator><creator>Hafez, Yasser Mostafa</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190815</creationdate><title>Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)</title><author>Atef, Marwa Mohamed ; Abd-Ellatif, Rania Nagi ; Emam, Marwa Nagy ; Abo El gheit, Rehab E. ; Amer, Alaa Ibrahim ; Hafez, Yasser Mostafa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-43b8460d02800bfe95564d41cb045544596cf4976ffdabde379208e210dca31e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Blood Glucose - metabolism</topic><topic>Citrate (si)-Synthase - metabolism</topic><topic>Estradiol - metabolism</topic><topic>Female</topic><topic>Insulin - metabolism</topic><topic>Letrozole</topic><topic>Lipid Metabolism - drug effects</topic><topic>Metformin</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondrial dynamics</topic><topic>Ovary - pathology</topic><topic>Oxidation-Reduction - drug effects</topic><topic>Polycystic ovary syndrome</topic><topic>Polycystic Ovary Syndrome - chemically induced</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Progesterone - metabolism</topic><topic>Rats</topic><topic>Selenium</topic><topic>Sodium Selenite - therapeutic use</topic><topic>Testosterone - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atef, Marwa Mohamed</creatorcontrib><creatorcontrib>Abd-Ellatif, Rania Nagi</creatorcontrib><creatorcontrib>Emam, Marwa Nagy</creatorcontrib><creatorcontrib>Abo El gheit, Rehab E.</creatorcontrib><creatorcontrib>Amer, Alaa Ibrahim</creatorcontrib><creatorcontrib>Hafez, Yasser Mostafa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of biochemistry and biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atef, Marwa Mohamed</au><au>Abd-Ellatif, Rania Nagi</au><au>Emam, Marwa Nagy</au><au>Abo El gheit, Rehab E.</au><au>Amer, Alaa Ibrahim</au><au>Hafez, Yasser Mostafa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)</atitle><jtitle>Archives of biochemistry and biophysics</jtitle><addtitle>Arch Biochem Biophys</addtitle><date>2019-08-15</date><risdate>2019</risdate><volume>671</volume><spage>245</spage><epage>254</epage><pages>245-254</pages><issn>0003-9861</issn><eissn>1096-0384</eissn><abstract>Polycystic ovary syndrome (PCOS) is the most common endorinopathy in fertile women with heterogeneous reproductive and metabolic phenotypes and unknown etiology. This study was undertaken to investigate the beneficial effect of selenium in management of letrozole induced PCOS and its role in modulating mitochondrial dynamics, and its associated signals. Twenty four adult female rats were enrolled and randomly divided into four equal groups; control group received 0.5% w/v carboxymethyl cellulose (CMC); PCOS group received letrozole (1 mg/kg, daily) in 0.5% CMC for 21 days. From day 22 to day 36, after letrozole PCOS induction, the (PCOS +Metformin) group received metformin (2 mg/kg, daily) while (PCOS + sodium selenite) group received sodium selenite (0.1 mg/kg, daily). All doses were given via oral gavage. At the study end, serum hormone levels, lipid profile and HOMA-IR were assessed. Ovaries were dissected, used for histopathological evaluation, immunohistochemical detection of B-cell lymphoma-2 (Bcl-2), and its associated X protein (Bax) expression, measurement of redox status, mitochondrial dynamics markers and citrate synthase (CS) activity. Furthermore Mitofusins 2 (Mfn2) and dynamin related protein 1 (Drp1) mRNA expression was assessed by real time PCR. Selenium treatment of PCOS rats succeeded, comparable to metformin, to greatly improve the PCOS associated endocrine and metabolic phenotypes and histopathological changes, mostly through modulating mitochondrial dynamics, anti-apoptotic action, alleviating oxidative stress and mitochondrial dysfunction. So, selenium could provide a novel therapeutic strategy for PCOS. •PCOS is a common endorinopathy but still with unsatisfactory management.•The search for treatment combating different lines of PCOS pathogenesis is needed.•Thus beneficial effect of selenium in modulating PCOS outcomes was investigated.•Selenium could provide a novel therapeutic strategy for PCOS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31251923</pmid><doi>10.1016/j.abb.2019.06.009</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-9861
ispartof Archives of biochemistry and biophysics, 2019-08, Vol.671, p.245-254
issn 0003-9861
1096-0384
language eng
recordid cdi_proquest_miscellaneous_2250631435
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Blood Glucose - metabolism
Citrate (si)-Synthase - metabolism
Estradiol - metabolism
Female
Insulin - metabolism
Letrozole
Lipid Metabolism - drug effects
Metformin
Mitochondria - metabolism
Mitochondrial dynamics
Ovary - pathology
Oxidation-Reduction - drug effects
Polycystic ovary syndrome
Polycystic Ovary Syndrome - chemically induced
Polycystic Ovary Syndrome - drug therapy
Progesterone - metabolism
Rats
Selenium
Sodium Selenite - therapeutic use
Testosterone - metabolism
title Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A32%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20potential%20of%20sodium%20selenite%20in%20letrozole%20induced%20polycystic%20ovary%20syndrome%20rat%20model:%20Targeting%20mitochondrial%20approach%20(selenium%20in%20PCOS)&rft.jtitle=Archives%20of%20biochemistry%20and%20biophysics&rft.au=Atef,%20Marwa%20Mohamed&rft.date=2019-08-15&rft.volume=671&rft.spage=245&rft.epage=254&rft.pages=245-254&rft.issn=0003-9861&rft.eissn=1096-0384&rft_id=info:doi/10.1016/j.abb.2019.06.009&rft_dat=%3Cproquest_cross%3E2250631435%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2250631435&rft_id=info:pmid/31251923&rft_els_id=S0003986119302838&rfr_iscdi=true